Pfizer And MPP Sign Deal For Generics Of COVID-19 Candidate Paxlovid
Tiered Pricing To Allow Equitable Access To Oral Antiviral
Executive Summary
An agreement allowing the production and distribution of the US firm’s new protease inhibitor in 95 countries has been welcomed by the Medicines Patent Pool. But some medicines access advocates are not so sure it necessarily represents a good deal for lower-income countries.
You may also be interested in...
Medicines Patent Pool Facilitates Deals With Seven Manufacturers For COVID-19 Antiviral
The Medicines Patent Pool has facilitated sublicenses with seven manufacturers to distribute generic versions of Shionogi’s oral COVID-19 antiviral ensitrelvir across low- and middle-income countries.
MPP Facilitates Agreements With Seven Manufacturers For COVID-19 Antiviral
The Medicines Patent Pool has facilitated sublicenses with seven manufacturers to distribute generic versions of Shionogi’s oral COVID-19 antiviral ensitrelvir across low- and middle-income countries.
A Year Of Paxlovid - Where Is The Licensed Generic?
A year since Paxlovid was launched and The Medicines Patent Pool licensed Pfizer’s nirmatrelvir, we look at a few likely reasons for authorized generics of Paxlovid not turning up and what lies ahead in 2023, as Hetero’s version becomes the first with WHO prequalification while two Chinese and a Korean company wait in the wings.